PRYaMOY INGIBITOR RENINA ALISKIREN - SAMOSTOYaTEL'NAYa STRATEGIYa KORREKTsII KARDIORENAL'NOGO SINDROMA PRI METABOLIChESKOM SINDROME I OZhIRENII
- Авторлар: Fomin VV1, Saginova EA1
-
Мекемелер:
- Шығарылым: № 4 (2010)
- Беттер: 76-80
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245907
- ID: 245907
Дәйексөз келтіру
Толық мәтін
Аннотация
Role of direct renin inhibitor aliskiren in halting the progression of chronic kidney disease in obesity and metabolic syndrome is discussed
Әдебиет тізімі
- Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004
- Ting S.M., Nair H., Ching I. et al. Overweight, obesity and chronic kidney disease. Nephron. Clin. Pract. 2009; 112(3): c121-c127
- Nelson R., Antonetti I., Bisognano J.D., Sloand J. Obesity-related cardiorenal syndrome. J. Clin Hypertens. 2010; 12(1): 59-63
- Мухин Н.А., Фомин В.В., Сагинова Е.А. и др. Эндотелиальная дисфункция и поражение почек при ожирении. Вестник РАМН 2006; 12: 32 - 37
- Bravo P.E., Morse S., Borne D.M., Aguilar E.A., Reisin E. Leptin and hypertension in obesity. Vasc. Health Risk Manag. 2006; 2(2):163-169
- Fruhbeck G. The adipose tissue as a source of vasoactive factors. Сurr. Med. Chem. Cardiovasc. Hematol. Agents. 2004; 2: 197 - 208
- Sowers J.R., Epstein M., Frohlich E.D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001; 37: 1053 - 1059
- Sarzani R., Salvi F., Dessì-Fulgheri P., Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J. Hypertens. 2008; 26(5): 831-843
- Engeli S., Schling P., Gorzelniak K. et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell Biol. 2003; 35(6): 807-825
- Nguyen G., Delarue F., Burcklé C. et al. Pivotal role of the renin/pro-renin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest/ 2002; 109:1417-1427
- Danser A.H.J., Deinum J. Renin, prorenin, and the putative prorenin receptor. Hypertension 2005; 46: 1069 - 1076
- Oliver J.A. Receptor mediated actions of renin and pro-renin. Kidney Int. 2006; 69: 13-15
- Huang Y., Wongamorntham S., Kasting J. et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006;69:105-113
- Nguen G., Danser A.H.J. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 2008; 93 (Pt.5): 557 - 563
- Ichihara A., Suzuki F., Nakagawa T. et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J. Am. Soc. Nephrol. 2006; 17:1950-1961
- Kaneshiro Y., Ichihara A., Sakoda M. et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)rennin receptor-transgenic rats. J. Am. Soc. Nephrol. 2007; 18:1789-1795
- Krebs C., Hamming I., Sadaghiani S. et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int. 2007; 72: 725-730
- He M., Zhang L., Shao Y. et al. Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur. J. Pharmacol. 2009; 606(1-3): 155-161
- Fisher N.D.L., Hollenberg N.K. Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol. 2005; 16: 592 - 599
- Staessen J.A., Li Y., Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449 - 1456
- Whaley-Connel A., Sowers J., Purkayastha D. et al. Combination therapy with aliskiren and hydrochlorothiazide decreases plasma renin activity and oxidative stress versus ramipril while reducing blood pressure in obese patients with stage 2 hypertension. J. Clin. Hypertens. 2010 ; 12(Suppl. 1) : A46
- Latini R., Masson S., Anand I. et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004; 25: 292 - 299
- Yeyati N.L., Adrogue H.J. Inappropriately high plasma renin activity accompanies chronic loss of renal function. Am. J. Nephrol. 1996; 16: 471 - 477
- Jordan J., Engeli S., Boye S.W. et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007; 49: 1047 - 1055
- Luetscher J.A., Kraemer F.B., Wilson D.M. et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular comlications. N. Engl. J. Med. 1985; 312: 1412 - 1417
- Chiarelli F., Pomilio M., De Luca F.A. et al. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr. Nephrol. 2001; 16: 116 - 120
- Kelly D.J., Zhang Y., Moe G. et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007; 50(11): 2398-2404
- Pilz B., Shagdarsuren E., Wellner M. et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005; 46(3): 569-576
- Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K.; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008; 358(23): 2433-2446
- Persson F et al. Renoprotective effects of direct renin inhibition compared to and in combination with maximum recommended dose of Irbesartan in patients with type 2 diabetes and albuminuria. Diabetologia 2008; 51 (Suppl 1): S492.
- Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 2009; 24(5): 1663 - 1671
- Delea T.E., Sofrygin O., Palmer J.L. et al. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. J. Am. Soc. Nephrol. 2009; 20(10): 2205-2213
Қосымша файлдар
![](/img/style/loading.gif)